MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2024 International Congress

    Pharmacokinetic Intersections in Geriatric Neuropharmacology: A Parkinson’s Disease Case Study with Concomitant Refractory Major Depressive Disorder

    D. Nolasco, L. Schmidt, B. Carr (Gainesville, USA)

    Objective: This investigation delineates the pharmacokinetic intricacies encountered in the therapeutic management of a geriatric patient with Parkinson’s Disease (PD) concomitantly suffering from refractory Major…
  • 2024 International Congress

    Validation of PD Ascertainment in the VA Electronic Medical Record (EMR)

    S. Goldman, F. Weaver, L. Cao, S. Jugnundan, B. Gonzalez, K. Stroupe, K. Colletta, E. Brown, C. Tanner (San Francisco, USA)

    Objective: To determine the validity of PD diagnostic codes in a large national electronic medical database and develop recommendations for maximizing ascertainment accuracy. Background: EMR-based…
  • 2024 International Congress

    Association between Non-Motor Parkinson’s disease symptoms and hyposmia in a population-based cohort

    C. Theyer, K. Marini, F. Krismer, C. Horlings, H. Stockner, K. Schwarzová, I. Egner, A. Djamshidian-Tehrani, M. Marti, R. Krüger, V. Satagopam, B. Mollenhauer, S. Schade, C. Trenkwalder, K. Rege, S. Ghosh, A. Garrido, E. Tolosa, T. Marques, D. Mcintyre, W. Poewe, K. Seppi, P. Mahlknecht (Innsbruck, Austria)

    Objective: To describe the association between different Parkinson’s disease (PD) related non-motor symptoms (NMS) and hyposmia in a population-based cohort. Background: Olfactory dysfunction is of…
  • 2024 International Congress

    Movement Disorder Society Unified Parkinson’s Disease Rating Scale Motor Examination Retains Its 2-Domain Profile in Both On and Off States

    T. Mestre, G. Stebbins, C. Goetz, S. Luo (Ottawa, Canada)

    Objective: This study aims to validate the two-domain structure of MDS-UPDRS Part III items in both medication states, exploring the discriminative ability of the tremor…
  • 2024 International Congress

    Responders to a Highly Challenging Balance and Gait Intervention in People with Parkinson’s Disease

    E. Franzén, H. Johansson, E. Westman, M. Hagströmer, F. Albrecht (Stockholm, Sweden)

    Objective: To characterize responsiveness to a highly challenging balance and gait intervention (HiBalance) in participants with Parkinson's disease (PD). Background: Exercise potentially improves gait, balance,…
  • 2024 International Congress

    An Innovative Approach Combining Transcranial Direct Current Stimulation and Speech Therapy for the Treatment of Dysphagia in Parkinson’s Disease.

    T. Bocci, G. Cosentino, S. Pierro, E. Concas, C. Pipolo, E. Fuccillo, M. Guidetti, A. Priori (Milano, Italy)

    Objective: Our study used a combined approach based on non-invasive neuromodulation and speech therapy to improve dysphagia in PD patients. Background: Dysphagia is one of…
  • 2024 International Congress

    Breaking Barriers to Offer Evidence-Based Services for Patients with Parkinson’s Disease in South Africa

    S. Govender, S. Haffejee (Johannesburg, South Africa)

    Objective: To provide evidence-based services for patients with Parkinson’s disease considering the burden of disease in South Africa (SA) and access, socio economic and technology…
  • 2024 International Congress

    Quality of life assessment in patients with Parkinson’s disease

    S. Frikha, O. Ben Othmen, M. Ben Mahmoud, S. Fray, H. Jamoussi, M. Fredj, N. Ben Ali (Tunis, Tunisia)

    Objective: The objective of the study was to assess the quality of life in patients with Parkinson's disease (PD) and to establish statistical correlations with…
  • 2024 International Congress

    A Phase 1b Randomized, Placebo-Controlled, Delayed-Start Trial of UB-312 in Synucleinopathies.

    P. Millar Vernetti, D. Mirski, JC. Dodart, A. Wood, HJ. Yu, J. Boyd, P. Kundu, R. Setton, D. Silbersweig, E. Stern, C. Lucero, S. Gerrol, H. Kaufmann, J. Martinez (New York, USA)

    Objective: Assess safety and immunogenicity of UB-312 in a phase 1b trial in Multiple System atrophy (MSA) or Parkinson’s disease (PD). Background: Abnormal deposition of…
  • 2024 International Congress

    Orthostatic hypotension in age-related neurodegenerative diseases: a bibliometric study from 2007 to 2023

    Y. Qu, B. Zhang, C. Xing, Y. Yuan (Xi'an, China)

    Objective: This study aims to systematically assess the current landscape and evolving trends of research on orthostatic hypotension in the context of age-related neurodegenerative diseases…
  • « Previous Page
  • 1
  • …
  • 53
  • 54
  • 55
  • 56
  • 57
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Survey-Based study of marijuana used in Parkinson’s Disease patients
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley